Dogwood Therapeutics (DWTX) investor relations material

Executive summary

• Special Meeting scheduled for March 11, 2026, to be held virtually for all stockholders of record as of February 12, 2026.

• Main items for vote: approval of the exercise of a common stock warrant and potential adjournment of the meeting if more votes are needed.

• Board of Directors unanimously recommends voting in favor of all proposals.

• Proxy materials are available both online and in paper form, with multiple voting methods provided.

Voting matters and shareholder proposals

• Proposal 1: Approve exercise of an unregistered common stock warrant to purchase up to 4,386,037 shares and issuance of shares under the Securities Purchase Agreement and Nasdaq Listing Rule 5635(d).

• Proposal 2: Approve adjournment of the Special Meeting to solicit additional proxies if needed.

• If Proposal 1 is not approved, repeated meetings will be required every three months until approval or expiration of the warrant.

• Board recommends a vote "FOR" both proposals.

• Stockholders can submit proposals for the 2026 Annual Meeting by December 31, 2025, or nominate directors following specific bylaw procedures.

Board of directors and corporate governance

• No director or executive officer has a substantial interest in the warrant proposal beyond that of other stockholders.

• Board members and executive officers collectively own 0.3% of outstanding shares as of January 22, 2026.